Resources from the same session
Rationale and development of PARPi adjuvant versus advanced or relapse: Ovary and breast examples
Presenter: F. André, FR and I. Ray-Coquard, FR
Session: Session 3 – Comparing efficacy of PARP inhibition across tumour types
Resources:
Slides
Webcast
What did we learn from Phase I trials with PARPi?
Presenter: J. Mateo, ES
Session: Session 3 – Comparing efficacy of PARP inhibition across tumour types
Resources:
Slides
Webcast